AbbVie, Umoja Biopharma Set CAR-T Cell Therapies Collaboration
05 January 2024 - 1:29AM
Dow Jones News
By Colin Kellaher
AbbVie has struck a pair of exclusive option and license
agreements with clinical-stage biotechnology company Umoja
Biopharma aimed at developing new chimeric antigen receptor T-cell,
or CAR-T, cancer therapy candidates.
AbbVie on Thursday said the companies plan to develop multiple
in-situ generated CAR-T cell therapy candidates using Umoja's
proprietary VivoVec platform.
AbbVie said it made upfront payments and an equity investment in
Umoja, which is eligible to receive up to $1.44 billion for option
exercise fees, development and regulatory milestones, along with
additional sales-based milestones and royalties on sales.
AbbVie said it has an exclusive option to license Umoja's CD19
directed in-situ generated CAR-T cell therapy candidates, including
Umoja's lead clinical program for hematologic malignancies, which
is currently at the IND-enabling phase.
The companies also plan to develop up to four additional
candidates for discovery targets selected by AbbVie, based in North
Chicago, Ill.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 04, 2024 09:14 ET (14:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Dec 2024 to Jan 2025
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jan 2024 to Jan 2025
